Asciminib demonstrates superior efficacy and safety in newly diagnosed chronic myeloid leukemia in the ASC4FIRST trial.
- DOI
- 10.1182/blood.2025029210
- Published
- 2026-03-01
- Container
- Blood
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1182/blood.2025029210,
title = {Asciminib demonstrates superior efficacy and safety in newly diagnosed chronic myeloid leukemia in the ASC4FIRST trial.},
author = {Cortes JE and Hughes TP and Wang J and Kim DW and Kim DDH and Mayer J and Goh YT and le Coutre P and Etienne G and Kim I and Andorsky DJ and Bombaci F and Issa GC and Takahashi N and Kapoor S and Jinwal R and Malek K and McCulloch T and Yau L and Larson RA and Hochhaus A.},
year = {2026},
journal = {Blood},
doi = {10.1182/blood.2025029210},
url = {https://doi.org/10.1182/blood.2025029210}
}RIS
TY - JOUR TI - Asciminib demonstrates superior efficacy and safety in newly diagnosed chronic myeloid leukemia in the ASC4FIRST trial. AU - Cortes JE AU - Hughes TP AU - Wang J AU - Kim DW AU - Kim DDH AU - Mayer J AU - Goh YT AU - le Coutre P AU - Etienne G AU - Kim I AU - Andorsky DJ AU - Bombaci F AU - Issa GC AU - Takahashi N AU - Kapoor S AU - Jinwal R AU - Malek K AU - McCulloch T AU - Yau L AU - Larson RA AU - Hochhaus A. PY - 2026 JO - Blood DO - 10.1182/blood.2025029210 UR - https://doi.org/10.1182/blood.2025029210 ER -
APA
JE, C., TP, H., J, W., DW, K., DDH, K., J, M., YT, G., P, L. C., G, E., I, K., DJ, A., F, B., GC, I., N, T., S, K., R, J., K, M., T, M., L, Y., RA, L., & A., H. (2026). Asciminib demonstrates superior efficacy and safety in newly diagnosed chronic myeloid leukemia in the ASC4FIRST trial.. Blood. https://doi.org/10.1182/blood.2025029210
Source records
- europe-pmc · retrieved 2026-09-26T03:29:38.368Z